LRMR - Larimar Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.00
DETAILS
HIGH:
$12.00
LOW:
$12.00
MEDIAN:
$12.00
CONSENSUS:
$12.00
UPSIDE:
247.83%
About Larimar Therapeutics, Inc. (https://www.larimartx.com)
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Carole S. Ben-Maimon | Chief Executive Officer, President & Director | 1959 | $976,403 USD |
| Michael Celano | Secretary & Chief Financial Officer | 1959 | $696,996 USD |
| Gopi Shankar | Chief Development Officer | 1971 | $642,351 USD |
| Francis Michael Conway | Vice President & Controller | – | – |
| Jennifer Spokes Johansson | Vice President of Legal & Compliance | – | – |
| John Berman | Vice President of Finance & Administration | – | – |
| Russell G. Clayton | Chief Medical Officer | 1961 | – |